Recently, the results of the third "AI Applications Star" (MINDS) project selection by the World Economic Forum were announced. Sino Biopharm (1177.HK), by virtue of its outstanding integration of artificial intelligence technology and its practice of full-chain digital transformation, has successfully been included in the authoritative international list as an independently applying pharmaceutical company, highlighting the company's technological advantages and forward-looking vision in AI-empowered pharmaceutical R&D. 

The World Economic Forum is one of the most influential international organizations globally, and its MINDS project represents the authoritative benchmark for the practical application of AI worldwide. The program aims to identify and showcase "Meaningful, Intelligent, Novel, and Deployable Solutions". Stephan Mergenthaler, Executive Director and Chief Technology Officer of the World Economic Forum, stated: "The fusion of artificial intelligence with various technologies is comprehensively reshaping business operations and societal functioning. "The AI Applications Star" program is dedicated to discovering, validating, and promoting the most impactful transformative cases, setting a new industry benchmark for artificial intelligence applications."

The project is rigorously reviewed and selected by an independent international impact committee composed of top executives and domain experts, based on criteria such as innovation, impact, and replicability. The 26 organizations selected this time come from 12 industries and 28 countries, covering fields such as energy, scientific discovery, and healthcare. The selected cases are categorized into six major impact areas: Accelerating Growth through Efficiency Gains and Technological Innovation, Building Sustainable Earth Energy and Food Systems, Creating Healthier Lives with Better Healthcare, Enhancing Learning and Expanding Skills, Safeguarding Trusted Information and Governance Mechanisms, and Building Resilient Infrastructure and Supply Chains. 

With its long-term investment in intelligent and digital transformation, Sino Biopharm has become one of the representatives in the healthcare sector. The company has built an enterprise-level AI operations system with a unified governance framework, deeply embedding professional AI agents into key clinical trial processes, medical promotion and commercial operations, and corporate management audits. This integrates previously scattered data, rules, and workflow nodes, promoting AI to become a fundamental capability supporting business operations. Currently, the system has been implemented at scale within the company, with significant improvements in key efficiency indicators: PCC discovery time has been shortened by over 50%, the center investigation and screening cycle has been reduced by about 30%, AI-centralized monitoring has increased risk identification efficiency by 85%, and the sales conversion rate for pilot products has increased by about 50%. 

This selection not only represents the recognition of Chinese pharmaceutical companies' AI practices by global authoritative institutions but also showcases to the world the innovative strength of Chinese pharmaceutical companies on the track of AI-driven industrial transformation. As a MINDS-selected company, Sino Biopharm will join the World Economic Forum's global network platform, participate in more international dialogues and collaborations, learn from the world's top AI application experiences, and export Chinese solutions to the world, thereby powerfully promoting the overall upgrade of China's pharmaceutical industry ecosystem. 

From intelligent screening and risk control in clinical trials to precise outreach in medical promotion, and automated auditing and decision support in corporate operations, Sino Biopharm has deeply embedded AI into every key link of the entire pharmaceutical chain, making intelligent agents a true fundamental capability supporting business operations. In the future, upholding the development philosophy of "Healthy Technology, Warming More Lives", the company will continue to deepen its AI operations system, explore more innovative application scenarios, accelerate its progress toward becoming a world-class pharmaceutical company, and allow good Chinese medicines to benefit more patients.